** Brokerage Scotiabank upgrades life sciences tool maker Waters Corp WAT.N rating to "sector outperform" from "sector perform", raises PT to $450 from $430
** Brokerage says the rating is based on WAT's strong Q4 financial performance and 2025 profit forecast
** The price target is justified due to the timing of its clients' instrument replacement cycles, significant revenue from life science applications, and a leading position in emerging markets such as GLP-1 obesity drugs and generic drugs in India - Scotiabank
** "On the bottom line, WAT continues to have significant EPS leverage, driven by its industry leading margins, recently initiated productivity and pricing initiatives and cash deployment capacity" - brokerage
** Stock rose 21.7% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.